Saturday, July 12, 2025

Latest

Mind Medicine Applies To List On The Nasdaq

Mind Medicine (NEO: MMED) this morning announced that it has submitted an application to uplist its stateside cross-listing to that of the Nasdaq Capital Market from the OTCQB. The submittal of an application is part of the firms goal of “evaluating an expanded United States investor base.”

Canaccord Genuity has been appointed as financial advisor in connection with the application, whom is said to be assessing the viability of such a move by the company. Canaccord is also said to be evaluating potential M&A opportunities for the firm.

No further information on the Nasdaq application was provided by the company, aside from the statement that no assurances can provided that the Nasdaq will approve of the application.

The appointment of Canaccord as financial advisory notably follows the news last week that Canaccord initiated coverage on the firm with a $1.75 price target.

Mind Medicine last traded at $0.53 on the Neo.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Mergers Set the Stage for Uranium’s Growth Cycle | Forum-Baselode Merger

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Recommended

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

Related News

Mind Medicine Closes The Year Out With Further Management Departures

Mind Medicine (NEO: MMED) has seen further management departures, following the departure of its CEO...

Wednesday, December 29, 2021, 08:38:09 AM

Mind Medicine Prices $30 Million Offering At 30% Discount To Market

Mind Medicine (NEO: MMED) has elected to destroy shareholder value in a major way this...

Wednesday, September 28, 2022, 09:28:04 AM

MindMed Acquires HealthMode For $41.6 Million

MindMed (NEO: MMED) this morning announced that it will be acquiring that of HealthMode in...

Thursday, February 18, 2021, 08:21:32 AM

MindMed Launches Clinical Trial Focused On Combining LSD With MDMA

Mind Medicine (NEO: MMED) has begun the first clinical trials focused on combining MDMA and...

Wednesday, January 20, 2021, 08:09:53 AM

Psychedelics & The Need For Digital Therapeutic Solutions In Treating Mental Health

In terms of investment dollar inflows, one of the largest focuses of 2020 has arguably...

Sunday, November 1, 2020, 09:00:00 AM